Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.
暂无分享,去创建一个
Don C Des Jarlais | Holly Hagan | David M Rindskopf | D. D. Des Jarlais | D. Rindskopf | H. Hagan | Janetta M. Astone-Twerell | S. Strauss | Shiela M Strauss | Janetta M Astone-Twerell
[1] Jeroen K. Vermunt,et al. 'EM: A general program for the analysis of categorical data 1 , 1997 .
[2] G. Dore,et al. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] B. Conway,et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] J. Sorensen,et al. HIV/Hepatitis Prevention in Drug Abuse Treatment Programs: Guidance From Research , 2002, Science & practice perspectives.
[5] J. Strang,et al. Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment , 1999, BMJ.
[6] T. Vaughn,et al. An organizational analysis of service patterns in outpatient drug abuse treatment units , 1995 .
[7] G. Bigelow,et al. Providing medical care to methadone clinic patients: referral vs on-site care. , 1994, American journal of public health.
[8] W. Lawson,et al. Correlates of patterns of substance abuse among patients with schizophrenia. , 1993, Hospital & community psychiatry.
[9] D. Goldberg,et al. Establishment of a database of diagnosed HCV-infected persons in Scotland. , 2003, Communicable disease and public health.
[10] D. D. Des Jarlais,et al. Gaps in the drug-free and methadone treatment program response to Hepatitis C. , 2003, Journal of substance abuse treatment.
[11] D. Baker. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. , 2003, Reviews in gastroenterological disorders.
[12] S. Tortu,et al. HEPATITIS C AMONG NONINJECTING DRUG USERS: A REPORT , 2001, Substance use & misuse.
[13] M. Stein,et al. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. , 2001, Drug and alcohol dependence.
[14] M. Alter,et al. Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.
[15] H. Grunze,et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups , 2003, Hepatology.
[16] Mary Ellen Kitler,et al. Global burden of disease (GBD) for hepatitis C , 2004 .
[17] A. McCutcheon,et al. Latent Class Analysis , 2021, Encyclopedia of Autism Spectrum Disorders.
[18] D. D. Jarlais,et al. A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. , 2004, Drug and alcohol dependence.
[19] M. Singer,et al. Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. , 2002, Addiction.
[20] S. Neri,et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. , 2002, Clinical therapeutics.
[21] L. Magder,et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt , 2000, The Lancet.
[22] L. Seeff,et al. Natural history of hepatitis C , 1997, Hepatology.
[23] D. Rindskopf,et al. The value of latent class analysis in medical diagnosis. , 1986, Statistics in medicine.
[24] M. Backmund,et al. Treatment of hepatitis C infection in injection drug users , 2001, Hepatology.
[25] D. D. Des Jarlais,et al. A nationwide survey of hepatitis C services provided by drug treatment programs. , 2002, Journal of substance abuse treatment.
[26] G. Woody,et al. The Effects of Psychosocial Services in Substance Abuse Treatment , 1993, JAMA.
[27] C. Horgan,et al. Access to services in the substance abuse treatment system. Variations by facility characteristics. , 2001, Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism.
[28] K. Bjøro,et al. Treatment of Chronic Hepatitis C in Injecting Drug Users: 5 Years’ Follow-Up , 2002, European Addiction Research.
[29] S. Mauss,et al. A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance , 2004, Hepatology.
[30] P McElroy,et al. An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units. , 1999, Journal of health and social behavior.
[31] A. Copeland,et al. Drug abuse treatment as an HIV prevention strategy: a review. , 2000, Drug and alcohol dependence.
[32] M. Layton,et al. Hepatitis C screening and management practices: a survey of drug treatment and syringe exchange programs in New York City. , 2002, American journal of public health.
[33] J. Hoofnagle,et al. Optimal therapy of hepatitis C , 2002, Hepatology.
[34] A. Rosenblum,et al. Hepatitis C and Substance Use in a Sample of Homeless People in New York City , 2001, Journal of addictive diseases.
[35] J. Duchin,et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. , 2001, American journal of public health.
[36] G. Dunteman,et al. Treatment services in two national studies of community-based drug abuse treatment programs , 1995 .
[37] S. Creech,et al. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse , 2003, American Journal of Gastroenterology.
[38] D. Sylvestre. Treating hepatitis C virus infection in active substance users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] S. Tortu,et al. Sharing of Noninjection Drug-Use Implements as a Risk Factor for Hepatitis C , 2004, Substance use & misuse.
[40] J. Sellwood,et al. Risk factors, clinical features and genotype distribution of diagnosed hepatitis C virus infections: a pilot for a sentinel laboratory-based surveillance. , 2003, Communicable disease and public health.
[41] M. French,et al. Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and nonusers. , 1999, Substance use & misuse.
[42] R. Booth,et al. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. , 2002, Addiction.
[43] P. Selwyn,et al. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. , 1993, Public health reports.
[44] J. Kaldor,et al. Epidemiology of hepatitis C virus infection in Australia. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[45] Inda,et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.
[46] J. Hoofnagle,et al. Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C , 2000, Annals of Internal Medicine.
[47] D. D. Des Jarlais,et al. Integrating hepatitis C services into existing HIV services: the experiences of a sample of U.S. drug treatment units. , 2005, AIDS patient care and STDs.
[48] D. D. Des Jarlais,et al. Provision of Hepatitis C Education in a Nationwide Sample of Drug Treatment Programs , 2003, Journal of drug education.
[49] B. Edlin. Prevention and treatment of hepatitis C in injection drug users , 2002, Hepatology.
[50] H. Hagan,et al. The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units , 2004, Journal of Urban Health.
[51] D. Rubin,et al. Testing the number of components in a normal mixture , 2001 .
[52] R. Hubbard,et al. Treatment structure and program services in the Drug Abuse Treatment Outcome Study (DATOS). , 1997 .
[53] D. Vlahov,et al. Correlates of Hepatitis C Virus Infections among Injection Drug Users , 1995, Medicine.